Contracts worth EUR 3.4m signed with US Biotech

RNS Number : 5057L

Venn Life Sciences Holdings PLC

12 January 2016

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Contracts worth EUR 3.4m signed with US Biotech

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that they have signed new contracts worth over €3.4m with a leading US based Biotechnology client.

These contracts are extensions of an existing Phase II programme. The work will commence immediately and run until the end of 2017 in multiple US and European sites.

Speaking about the agreement, Venn CEO, Tony Richardson stated: "During 2015, I commented that executing our work to a consistent high standard would bring significant rewards and I am delighted to be able to show the concrete evidence of this. This is the second extension of what is a complex international programme and this endorsement is well deserved by our team. It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business."    

Enquiries:

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer		Tel: [phone]
Orla McGuinness, Marketing Manager		Tel: [phone]
Zeus Capital (Nominated Adviser and Joint Broker)		Tel: [phone]
Andrew Jones / Phil Walker
Dominic Wilson / Alex Davis
Hybridan LLP (Joint-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

For more information about the Company, please visit: www.vennlifesciences.com

 

END

 

 

MSCQFLFFQFFEBBD